{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-24-012156","form_type":"8-K","ticker":"CING","cik":"0001862150","company_name":"Cingulate Inc.","filed_at":"2024-04-01T23:59:59+00:00","discovered_at":"2026-05-14T18:03:20.957520+00:00","generated_at":"2026-06-04T04:58:47.296724+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Cingulate FY2023 net loss $23.5M; cash $52k; raised $10.7M in Q1 2024","bullets":["Net loss widened to $23.5M in 2023 from $17.7M; R&D expense $15.5M (+72% YoY).","Cash only $52k at year-end; $10.7M raised in Q1 2024 via ATM ($3.2M) and public offering ($7.5M).","CTx-1301 Phase 3 adult data showed trend vs placebo but not statistically significant; effect size highlighted.","FDA supports 505(b)(2) path for CTx-2103 (anxiety); IND design agreed.","Jennifer Callahan promoted to CFO; three independent directors added in Feb 2024."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-24-012156","json":"https://secwatch.observer/filing/0001493152-24-012156.json","markdown":"https://secwatch.observer/filing/0001493152-24-012156.md","text":"https://secwatch.observer/filing/0001493152-24-012156.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1862150/000149315224012156/0001493152-24-012156-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1862150/000149315224012156/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-04T04:58:47.296724+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"50b9c544a8bdd3925cf93ea5a207b124e0a1dfcc","claim":"Cingulate Inc. reported financial results for the twelve months ended December 31, 2023.","evidence_excerpt":"On April 1, 2024, Cingulate Inc. issued a press release announcing its financial results for the year ended December 31, 2023","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1862150/000149315224012156/0001493152-24-012156-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the twelve months ended December 31, 2023"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}